Skip to main content
. 2016 Jul 11;21(6):1191–1195. doi: 10.1007/s10147-016-1019-4

Table 1.

Characteristics of patients with bone metastasis who were treated with bone-modifying agents

Variables
Age (years) 71.5 (64.9–76.7)a
Male/female (cases) 101/17
Disease (cases) renal cell cancer/urothelial cancer/prostate cancer 22/27/69
First-line bone-modifying agent (case)
 Zoledronic acid 57
 Denosumab 61

aNumbers represent median (IQR)